Home / Tag Archives: DKA

Tag Archives: DKA

SGLT Inhibitors Protect the Heart and Kidneys: Why Is Type 1 Diabetes Still the Exception?

SGLT inhibitor medication with glucose monitoring supplies and heart and kidney imagery representing potential cardiorenal benefits in type 1 diabetes.

SGLT inhibitors have changed the treatment landscape for cardiovascular and kidney disease, particularly in people with type 2 diabetes, heart failure, and chronic kidney disease. That success raises an obvious question: why are SGLT inhibitors in type 1 diabetes still largely outside routine clinical practice? The answer is not a …

Read More »

Beyond A1C: Can CGM Help Prevent Severe Hypoglycemia and DKA?

Person using a continuous glucose monitor to track glucose levels and help prevent severe hypoglycemia and DKA.

Continuous glucose monitoring has changed how clinicians and people with diabetes think about glucose control. Yet the next question is more important than whether CGM improves A1C or Time in Range. Can it prevent events that send patients to the emergency department or hospital? Growing evidence suggests that CGM may …

Read More »

The Hidden Hyperglycemia Trigger: When Dehydration Makes Blood Sugar Worse

Person with diabetes reaching for water beside a glucose meter, illustrating how dehydration can worsen high blood sugar.

For people with diabetes, an unexpected glucose spike may have a less obvious cause than food or missed medication. Dehydration and high blood sugar can create a self-reinforcing cycle. When the body loses too much fluid, glucose becomes more concentrated in the bloodstream. At the same time, rising glucose can …

Read More »

Fasting or Random Glucose Testing? Navigating the New Rules for Cancer Therapy–Induced Hyperglycemia

Healthcare professional performing glucose testing on a cancer patient receiving treatment, illustrating monitoring for cancer therapy–induced hyperglycemia during oncology care.

As cancer treatment becomes increasingly sophisticated, clinicians are encountering a growing metabolic challenge. Cancer therapy–induced hyperglycemia has emerged as an important concern with the expanding use of immunotherapies and targeted therapies. In some patients, hyperglycemia develops gradually. In others, particularly those receiving immune checkpoint inhibitors, severe diabetes and diabetic ketoacidosis …

Read More »

What Really Happens When Patients Stop Insulin Without Telling Their Doctor?

Patient with diabetes sitting at a table with insulin supplies and glucose monitoring equipment, illustrating the risks of stopping insulin therapy without medical supervision.

For many people living with diabetes, insulin is more than a medication—it is a lifeline. Yet despite its critical role, some patients stop taking insulin without informing their healthcare provider. The reasons vary widely and may include medication costs, treatment fatigue, fear of side effects, weight gain concerns, or misunderstandings …

Read More »

GLP‑1s in Type 1 Diabetes With Obesity: When Do the 2026 Rules Say “Yes”?

A woman with type 1 diabetes and obesity consults with her doctor about GLP‑1 therapy, with insulin and diabetes tools visible.

Imagine managing type 1 diabetes and still gaining weight despite careful insulin use, exercise, and carb counting. That’s the frustrating reality for many people living with T1D and obesity. While insulin is life-saving, it can also promote weight gain, making the balance between glucose control and healthy weight even harder. …

Read More »